Pyxis Oncology, Inc. Federal Income Tax Expense (Benefit), Continuing Operations
Pyxis Oncology, Inc. (PYXS) reported Federal Income Tax Expense (Benefit), Continuing Operations of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Income Tax
us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations · last filed 2026-08-13
- Pyxis Oncology, Inc. federal income tax expense (benefit), continuing operations for the quarter ending 2026-06-30 was $0.00.
- Pyxis Oncology, Inc. federal income tax expense (benefit), continuing operations for the quarter ending 2026-03-31 was $0.00.
- Pyxis Oncology, Inc. federal income tax expense (benefit), continuing operations for the quarter ending 2025-09-30 was $0.00.
- Pyxis Oncology, Inc. federal income tax expense (benefit), continuing operations for the quarter ending 2025-06-30 was $0.00.
| Period end | Federal Income Tax Expense (Benefit), Continuing Operations 3 month | Federal Income Tax Expense (Benefit), Continuing Operations 6 month | Federal Income Tax Expense (Benefit), Continuing Operations 9 month |
|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-13 | $0.00 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-14 | ||
| 2025-09-30 | $0.00 10-Q · filed 2025-11-03 | $0.00 derived: sum of 2 quarters · filed 2026-08-13 | $0.00 10-Q · filed 2025-11-03 |
| 2025-06-30 | $0.00 10-Q · filed 2026-08-13 | $0.00 10-Q · filed 2026-08-13 | |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-14 | ||
| 2024-09-30 | $0.00 10-Q · filed 2025-11-03 | $0.00 derived: sum of 2 quarters · filed 2025-11-03 | $0.00 10-Q · filed 2025-11-03 |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-14 | $0.00 10-Q · filed 2025-08-14 | |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-15 | ||
| 2023-09-30 | $0.00 10-Q · filed 2024-11-12 | $0.00 derived: sum of 2 quarters · filed 2024-11-12 | $0.00 10-Q · filed 2024-11-12 |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-14 | $0.00 10-Q · filed 2024-08-14 | |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-14 | ||
| 2022-09-30 | $0.00 10-Q · filed 2023-11-07 | $0.00 derived: sum of 2 quarters · filed 2023-11-07 | $0.00 10-Q · filed 2023-11-07 |
| 2022-06-30 | $0.00 10-Q · filed 2023-08-11 | $0.00 10-Q · filed 2023-08-11 | |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-11 | ||
| 2021-09-30 | $0.00 10-Q · filed 2022-11-01 | $0.00 derived: sum of 2 quarters · filed 2022-11-01 | $0.00 10-Q · filed 2022-11-01 |
| 2021-06-30 | $0.00 10-Q · filed 2022-08-15 | $0.00 10-Q · filed 2022-08-15 | |
| 2021-03-31 | $0.00 10-Q · filed 2022-05-13 | ||
| 2020-09-30 | $0.00 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |